within Pharmacolibrary.Drugs.ATC.C;

model C03DA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.67,
    Cl             = 20.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.013300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008833333333333334,
    Tlag           = 840
  );

  annotation(Documentation(
    info ="<html><body><p>Spironolactone is a potassium-sparing diuretic and an antagonist of aldosterone. It is primarily used to treat conditions such as heart failure, hypertension, primary hyperaldosteronism, and edema associated with liver cirrhosis or nephrotic syndrome. It is also used for treatment of hirsutism and acne in women. Spironolactone is an approved drug and is commonly used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Lass, J, et al., &amp; Lutsar, I (2024). Pharmacokinetics of oral spironolactone in infants up to 2 years of age. <i>European journal of clinical pharmacology</i> 80(2) 239–248. DOI:<a href=&quot;https://doi.org/10.1007/s00228-023-03599-w&quot;>10.1007/s00228-023-03599-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38041740/&quot;>https://pubmed.ncbi.nlm.nih.gov/38041740</a></p></li><li><p>Regidor, PA, et al., &amp; Mayr, M (2023). Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. <i>Women&#x27;s health (London, England)</i> 19 17455057221147388–None. DOI:<a href=&quot;https://doi.org/10.1177/17455057221147388&quot;>10.1177/17455057221147388</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744531/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744531</a></p></li><li><p>Manjaly, C, et al., &amp; Mostaghimi, A (2023). Clascoterone for treatment of acne. <i>Drugs of today (Barcelona, Spain : 1998)</i> 59(2) 71–81. DOI:<a href=&quot;https://doi.org/10.1358/dot.2023.59.2.3507749&quot;>10.1358/dot.2023.59.2.3507749</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36811407/&quot;>https://pubmed.ncbi.nlm.nih.gov/36811407</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C03DA01;
